About DrugPatentWatch
Pharmaceutical Patent Intelligence Since 2002
DrugPatentWatch.com helps pharmaceutical companies, investors, consultants, attorneys, and researchers understand the competitive landscape surrounding branded drugs, generic entry, and pharmaceutical exclusivity.
For more than two decades, DrugPatentWatch has transformed complex pharmaceutical patent and regulatory information into actionable business intelligence.
The platform tracks:
- Drug patents and expiration dates
- FDA exclusivities
- Paragraph IV patent challenges
- ANDA filings and generic competition
- Biosimilar competition
- Patent litigation
- Licensing and settlement activity
- Drug lifecycle management strategies
Turning Patent Data Into Competitive Advantage
DrugPatentWatch was built on a simple idea:
Pharmaceutical patent information should be understandable, searchable, and commercially useful.
Patent filings, FDA records, litigation documents, and exclusivity data are often fragmented across multiple systems and difficult to interpret without deep industry expertise.
DrugPatentWatch organizes and connects that information into a structured intelligence platform that helps users:
- Forecast generic entry and loss of exclusivity
- Identify competitive threats
- Analyze patent strength and litigation risk
- Monitor biosimilar and generic market opportunities
- Support business development and licensing decisions
- Track evolving pharmaceutical competitive dynamics
Trusted Across the Pharmaceutical Industry
DrugPatentWatch is used by organizations across the global healthcare ecosystem, including:
- Pharmaceutical and biotech companies
- Generic drug manufacturers
- Biosimilar developers
- Competitive intelligence teams
- Business development groups
- Investment firms and analysts
- Law firms and patent professionals
- Consultants and market researchers
- Academic and healthcare institutions
Users rely on DrugPatentWatch to quickly understand how patent and exclusivity events can influence market access, pricing, competition, and commercial strategy.
More Than a Patent Database
DrugPatentWatch combines:
- Patent intelligence
- FDA regulatory data
- Litigation tracking
- Market forecasting
- Competitive analysis
- Business journalism
- AI-powered data tools
The platform is designed to help users move beyond raw patent documents and toward strategic decision-making.
Built for the Modern Pharmaceutical Market
The pharmaceutical industry moves quickly:
- Patents are challenged earlier
- Generic competition accelerates
- Biosimilar pathways evolve
- Licensing activity expands globally
- AI is reshaping healthcare research and intelligence
DrugPatentWatch helps organizations keep pace by delivering timely, structured, and commercially relevant pharmaceutical intelligence.
About the Founder
DrugPatentWatch was founded by Yali Friedman, a pharmaceutical industry analyst and entrepreneur focused on making complex pharmaceutical business intelligence more accessible and actionable.
Friedman launched DrugPatentWatch in 2002 after recognizing that pharmaceutical patent data was critically important but unnecessarily difficult to access and interpret.
Under his leadership, DrugPatentWatch became one of the most widely recognized independent resources for pharmaceutical patent and exclusivity intelligence.
Friedman is also the founder of DrugChatter, a platform focused on monitoring AI-driven and digital conversations about drugs and healthcare.
His work focuses on helping pharmaceutical organizations understand how patents, regulation, competition, and AI-driven information systems shape the future of the healthcare industry.
Explore DrugPatentWatch
- Research pharmaceutical patents and exclusivities
- Track generic and biosimilar competition
- Monitor patent litigation and Paragraph IV challenges
- Forecast loss of exclusivity events
- Support licensing and business development decisions
- Analyze pharmaceutical competitive landscapes
Visit DrugPatentWatch.com to learn more.
